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Abstract. Expression of the tumor supressor gene product 
p53 in thirteen human small intestinal tumors was examined 
employing an immunohistochemical technique. The level of 
p53 was analysed using the monoclonal antibody pAb240. 
Six out of thirteen tumors (46%) including one lymphoma, 
one angiosarcoma of the jejunum, one leiomyosarcoma, one 
adenocarcinoma of the small intestine and two metastatic 
adenocarcinomas of the colon were found to have p53 
overexpression. This is the first demonstration of p53 
expression in small intestinal tumors. These results indicate 
that the p53 gene may be involved in the pathogenesis of 
small intestinal tumors. 
Introduction 
Small intestine tumors are rare in comparison with those of 
the colon, although the former represents the largest part of 
the length and mucosal surface of the bowel (1,2). They 
consist of a wide range of both benign and malignant 
neoplasms of different origin (3,4). The information 
concerning the molecular basis of these tumors is limited (5). 
In a previous study we examined the ras oncogene family 
activation and gene product expression in a series of small 
intestinal tumors. We found Η-ras mutations and elevated 
ras p21 oncoprotein in 30% and 62% of the cases 
respectively suggesting a possible role of ras oncogene in the 
pathogenesis of these tumors (6). 
This study, to our knowlege is the first to assess p53 
expression in small intestine tumors and represents the 
continuation of our previous work in the same series of 
neoplasms where ras expression was studied (6). 
p53 expression was examined with the microwave post 
fixation streptavidin - Horse Radish Peroxidase (HRP) 
immunohistochemical method using the monoclonal 
antibody pAb240 (7). 
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Materials and methods 
Tissue specimens. Sections from paraffin-embedded tissue 
from tumors of human small intestine were obtained from the 
Air Forces General and V.A. Hospital, Athens and the 
University Hospital, Heraklion, Greece. The histological 
types of the tumors are shown in Table I. 
Immunohistochemistry. Immunohistochemical analysis of 
p53 was undertaken using the monoclonal antibody (mouse) 
pAb240 (Oncogene Science) (7). Serial sections were cut 
from all paraffin blocks at 5 μπι and mounted on Vectabond 
treated glass slides. The slides were air dried at room 
temperature for at least 24 hours. Then sections were 
dewaxed, rehydrated and endogenous peroxidase activity was 
blocked with 0.6% H 2 0 2 in 80% methanol for 20 min. After 
the sections were washed with double distilled water 
(ddH20) and placed in a plastic container (Sigma) filled with 
the following solution: 0.01 M sodium citrate Na,C6H507.H20, 
0.01 M HCl/Sodium citrate buffer pH 6.0. The jar was 
irradiated in a BioRad Polaron H2500 microwave processor 
(BioRad, Watford, Hertfordshire, UK) for 10 min (2x5) min 
at a power output equivalent to 600 W ensuring that there 
had been no loss of buffer during the first cycle. It has been 
shown that the above treatment is superior in unmasking p53 
protein, in routine material, compared to conventional 
enzymatic tratment (8). 
The sections were then rinsed in ddH20 water and TBS 
(Tris-buffered saline (0.05 mol/1 Tris-HCl, 0.1 mol/1 NaCl, 
pH 7.2). The second incubation was in biotinylated rabbit 
anti-mouse (Fab(ab')2 fragment) (Dako, Denmark) diluted 
1:200 TBS for 25 min and the third, after a wash with ddH
:
0 
and TBS, was streptavidin-HRP (Dako, Denmark) diluted 
1:300 TBS for 25 min. Signal was developed using 
diaminobenzidine (DAB) and hydrogen peroxide. After 
slides were air dried at 37°C counterstained, dehydrated and 
mounted. p53-expressing lung carcinomas were used as 
positive controls and as negative control, mouse IgGl mAb 
of unrelated specificity and the IgG fraction of normal rabbit 
serum. All p53 positive nuclei were counted on the 
specimens and the following semi-quantitative method was 
used: (±) = negative or equivocal (<5% positive cells), (+) = 
weak/moderate (5-50% positivity) and (++) = intensely 
positive (>50% positivity). 
886 SPANDIDOS et al: p53 EXPRESSION IN SMALL INTESTINAL TUMORS 
Table I. lmmunohistochemical staining of p53 protein in 13 
human small intestinal tumors. 
Type of tumor 
1. Hyperplastic - metaplastic polyp 
2. Adenomatous and papillary polyp 
of duedenum 
3. Adenomatous polyp of the small intestine 
4. Brunner's gland adenoma of the duedenum 
5. Neurilemoma 
6. Leiomyoma 
7. Carcinoid 
8. Lymphoma 
9. Angiosarcoma of the jejunum 
10. Leiomyosarcoma 
11. Adenocarcinoma of the small intestine 
12. Metastatic adenocarcinoma of the colon 
13. Metastatic adenocarcinoma of the colon 
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Figure 2. Strong p53 immunodetection, stained with pAb240, in MALT 
lymphoma (arrows) (X400). 
Figure 1. Weak p53 immunodetection, stained with pAb240, in 
leiomyosarcoma (arrows) (X400). 
Results 
Thirteen small intestine tumors were assessed for p53 levels 
of expression using the monoclonal antibody pAb240. 6/13 
(46%) of the tumors showed immunoreactivity for p53 
protein (Table I). The pattern of immunoreactivity was 
exclusively nuclear (Figs. 1, 2 and 3) Interestigly there was 
p53 reactivity in normal epithelium (Fig. 4). Variations were 
observed in the persentage of reactive cells ranging from 5 to 
90% (Table I). Variations in the intensity of staining between 
nuclei of the same tumor were also observed (Figs. 1, 2 
and 3). 
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Figure 3. Strong p53 immunodetection, stained with pAb240 in an 
undifferentiated metastatic tumor from a large bowel carcinoma (X200). 
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Figure 4. Strong p53 immunodetection stained with pAb240, in normal 
small intestine crypt (arrows) (X400). 
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Discussion 
Inactivation of tumor suppressor genes is involved in the 
pathogenesis of several human cancers (9). Such genes are 
the retinoblastoma (Rb), the p53 and the nrrili gene. The p53 
gene encodes a nuclear protein which plays an important role 
in the regulation of normal cell growth (10). 
Point mutations in the p53 gene result in an increased 
stability of the mutant protein, which can be detected by 
immunohistochemistry, whereas the wild-type p53 protein is 
undetectable, due to its short half-life (11). This approach has 
been used successfully to screen for p53 mutations in various 
tumors (12). 
In this study we analysed the expression of p53 protein in 
13 small intestine tumors with the use of the monoclonal 
antibody pAb240 which is known to recognize the mutant 
form of thep53. 
Our analysis revealed that p53 nuclear phosphoprotein is 
overexpressed in 46% of small intestine tumors. Intense p53 
expression (positivity >50% of the cells) was observed only 
in the MALT lymphoma, and the two metastatic adeno­
carcinomas of the colon while the remaining positive cases 
showed moderate p53 staining (positivity 5-50% of the cells). 
None of the benign small intestine neoplasms showed p53 
immunoreactivity although p53 protein was detected in 
rap id ly pro l i fe ra t ing crypt ce l l s in n o r m a l i n t e s t i n e 
epithelium. The latter is in accordance with several studies 
which show inconsistencies between the accumulation of p53 
protein identified by immunohistochemistry and direct 
sequencing of the gene (13). These reports propose that 
p A b 2 4 0 pos i t iv i ty does not a lways equate with p 5 3 
mutations. In this case p53 could be represented by the wild-
type p53 protein. It has been shown previously that in rapidly 
proliferating cells the wild-type protein can be expressed at 
immunohistochemically detectable levels (14,15). 
Assuming that the immunohistochemical demonstration 
of p53, particularly by pAb240 indicates in most of the cases 
the mutant prote in, these resul ts show a role for p53 
abnormalities in the malignant progression of small intestine 
neoplasms. 
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